biothera_revSlide thumbnail

Pharmaceutical Inc.

Biothera Pharmaceutical Inc. is developing Imprime PGG, a clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from randomized and single-arm phase 2 studies in non-small cell lung cancer, colorectal cancer, and chronic lymphocytic leukemia. Studies are ongoing in metastatic colorectal cancer and non-Hodgkin lymphoma.

Learn more »

Health Inc.

Biothera recently sold Biothera Health Inc., the manufacturer of Wellmune®, the natural food, beverage and supplement ingredient, to Kerry Group plc. Wellmune is clinically proven to strengthen the immune system and provides a range of health benefits, making it easier for consumers of all ages to be well and stay well. For information about Wellmune, go to